Federico Navarria

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 514 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

The impact of time to treatment initiation on survival from head and neck cancer in north-eastern Italy

Jerry Polesel, Carlo Furlan, Silvia Birri et al. · Oral Oncology · 2017 · 65 citations

Medicine, Oncology, Cancer Epidemiology +10

The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)–cT3 rectal cancer

Vincenzo Valentini, Maria Antonietta Gambacorta, Francesco Cellini et al. · Radiotherapy and Oncology · 2019 · 62 citations

Medicine, Oncology, Surgery +16

Defining the role of neoadjuvant systemic therapy in high‐risk retroperitoneal sarcoma: A multi‐institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group

William W. Tseng, Francesco Barretta, Lorenzo Conti et al. · Cancer · 2020 · 48 citations · Full text

Medicine, Oncology, Surgery +17

Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study

Marco Lupattelli, Fabio Matrone, Maria Antonietta Gambacorta et al. · Radiation Oncology · 2017 · 38 citations · Full text

Medicine, Oncology, Radiation Oncology +17